南京医药(600713.SH)拟通过并购基金投资生物材料和再生医学领域平台型研发公司

智通财经网05-21

智通财经APP讯，南京医药(600713.SH)发布公告，公司拟出资不超过4.5亿元，与南京新工新兴产业投资管理有限公司、南京新工医疗健康强链并购股权投资基金合伙企业(有限合伙)共同投资设立南京医药集团大清医疗器械强链并购股权投资有限责任公司(暂定名，简称“大清并购基金”)。大清并购基金成立后，专项投资不超过7.5亿元用于并购北京大清生物技术股份有限公司44.95%股权和北京科健科技有限公司...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2637381578?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-21 17:22","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2637381578","market":"hk","top_or_hot":-1,"title":"南京医药(600713.SH)拟通过并购基金投资生物材料和再生医学领域平台型研发公司","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，南京医药(600713.SH)发布公告，公司拟出资不超过4.5亿元，与南京新工新兴产业投资管理有限公司、南京新工医疗健康强链并购股权投资基金合伙企业(有限合伙)共同投资设立南京医药集团大清医疗器械强链并购股权投资有限责任公司(暂定名，简称“大清并购基金”)。大清并购基金成立后，专项投资不超过7.5亿元用于并购北京大清生物技术股份有限公司44.95%股权和北京科健科技有限公司...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1444527.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>南京医药(600713.SH)拟通过并购基金投资生物材料和再生医学领域平台型研发公司</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n南京医药(600713.SH)拟通过并购基金投资生物材料和再生医学领域平台型研发公司\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-21 17:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1444527.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，南京医药(600713.SH)发布公告，公司拟出资不超过4.5亿元，与南京新工新兴产业投资管理有限公司、南京新工医疗健康强链并购股权投资基金合伙企业(有限合伙)共同投资设立南京医药集团大清医疗器械强链并购股权投资有限责任公司(暂定名，简称“大清并购基金”)。大清并购基金成立后，专项投资不超过7.5亿元用于并购北京大清生物技术股份有限公司44.95%股权和北京科健科技有限公司...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1444527.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0250","symbol_name":"批发","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1444527.html","article_id":"2637381578","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637381578","pubTimestamp":1779355326,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，南京医药 发布公告，公司拟出资不超过4.5亿元，与南京新工新兴产业投资管理有限公司、南京新工医疗健康强链并购股权投资基金合伙企业共同投资设立南京医药集团大清医疗器械强链并购股权投资有限责任公司。据悉，并购标的属于生物材料和再生医学领域平台型研发公司，主要产品为植入类生物材料，拥有外科止血材料和骨修复材料核心产品，围绕生物材料和再生医学领域建立了多种材料制备技术平台。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600713":"南京医药","BK0250":"批发","BK0209":"零售"},"translate_title":"Nanjing Pharmaceutical (600713.SH) intends to invest in platform R&D companies in the fields of biomaterials and regenerative medicine through M&A funds","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600713":1.5},"content_text":"智通财经APP讯，南京医药(600713.SH)发布公告，公司拟出资不超过4.5亿元，与南京新工新兴产业投资管理有限公司、南京新工医疗健康强链并购股权投资基金合伙企业(有限合伙)共同投资设立南京医药集团大清医疗器械强链并购股权投资有限责任公司(暂定名，简称“大清并购基金”)。大清并购基金成立后，专项投资不超过7.5亿元用于并购北京大清生物技术股份有限公司44.95%股权和北京科健科技有限公司50.98%股权(合称“并购标的”)。据悉，并购标的属于生物材料和再生医学领域平台型研发公司，主要产品为植入类生物材料，拥有外科止血材料和骨修复材料核心产品，围绕生物材料和再生医学领域建立了多种材料制备技术平台。通过多年经营，并购标的具有技术研发优势、营销优势、品牌优势以及管理团队优势等市场竞争优势，为并购标的发展提供持续驱动力。并购标的与公司跨地区、广泛的业务网络和供应链体系具有良好协同互补效应，通过公司多维度赋能，预计能够加速并购标的核心产品价值转化，拓宽收入边界。公司与并购标的深度协作有利于推动公司产业转型升级，增强行业竞争力。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637381578","isCrawlerRequest":true}